Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 5,826

Document Document Title
WO/2010/113225
The present invention provides a novel transdermal patch containing high concentration of riluzole and being able to administer transdermally and quantitatively the drug to the ALS patients having difficulties taking the drug orally. Fur...  
WO/2010/113834
Disclosed is a novel and excellent method for preventing and/or treating cannabinoid-2 receptor-related diseases, which is based on an agonist action on cannabinoid-2 receptors. Specifically disclosed is a heterocyclic derivative mainly ...  
WO/2010/112091
Compounds of formula (I) wherein R1, R2, R3, X, and Y are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.  
WO/2010/112093
Compounds of formula (I), wherein R1, R2, R3, X and n are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.  
WO/2010/112092
Compounds of formula (I) wherein R1, R2, R3, R4, L1, and n are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.  
WO/2010/108843
The present invention relates to the use of nitric oxide releasing derivatives of paracetamol for retarding or reversing muscular dystrophies such as Duchenne and Becker dystrophies.  
WO/2010/109386  
WO/2010/106295
The invention relates to decorin for increasing muscle mass, in particular in the treatment of muscular dystrophies.  
WO/2010/108001
Methods of treating solid organ injuries using compounds that enhance Wnt signalling are described.  
WO/2010/108001
Methods of treating solid organ injuries using compounds that enhance Wnt signalling are described.  
WO/2010/104024
Disclosed is a piperazine compound represented by general formula (I) or a salt thereof. [In the formula, R1 represents an alkyl group having 1 to 6 carbon atoms; R2 represents any one selected from a hydroxy group, an alkyl group having...  
WO/2010/095663
Disclosed is a compound represented by formula (I) or a salt thereof, which has GPR 119 agonist action and excellent medicinal effects useful for prevention/treatment of diabetes, adiposis and the like. In the formula, P represents a sub...  
WO/2010/093784
The present invention provides AAV capsid proteins (VP1, VP2 and/or VP3) comprising a modification in the amino acid sequence in the three-fold axis loop 4 and virus capsids and virus vectors comprising the modified AAV capsid protein. I...  
WO/2010/093322
The present invention relates to methods for identifying therapeutic agents capable of modulating the activity of the IGF2 repressor ZBED6 for use in growth promotion,wound healing, angiogenesis, inhibition of muscle wasting, and treatme...  
WO/2010/093784
The present invention provides AAV capsid proteins (VP1, VP2 and/or VP3) comprising a modification in the amino acid sequence in the three-fold axis loop 4 and virus capsids and virus vectors comprising the modified AAV capsid protein. I...  
WO/2010/092966
Disclosed is a novel compound having P2X3 or P2X2/3 receptor antagonistic effect. Specifically disclosed is a compound represented by formula (I). (In the formula, (a) Ra and Rb combine together to form =Z, and Rc is a group represented...  
WO/2010/087306
Disclosed is a novel anti-neurodegenerative disease agent. The anti-neurodegenerative disease agent comprises a compound represented by general formula (1) as an active ingredient. In general formula (1), R1 to R3 independently represen...  
WO/2010/086040
Compounds of formula (I) wherein R1, R2, R3, R4, R5, L1, L2, m, and n are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.  
WO/2010/087313
Disclosed is a novel neurite elongation stimulator. The neurite elongation stimulator comprises a compound represented by general formula (1) as an active ingredient. In general formula (1), R1 to R3 independently represent a hydrogen a...  
WO/2010/087244
A novel low-molecular compound having an immunosuppressive action. The compound is a compound having general formula (I) or a pharmacologically acceptable salt thereof. [In the formula, the substituents are defined as shown below: R1 and...  
WO/2010/084999
Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases, which contain the substances (for example, anti-galectin-9 antibody, anti-Tim-3 antibody, RNA and DNA aptamers and low molecular substances) blocki...  
WO/2010/081862
The present invention relates to the use of a polyamine or a salt, solvate, or derivative thereof, such as spermine or spermidine for the treatment or prevention of a life threatening condition, such as multiple organ failure, in a criti...  
WO/2010/081862
The present invention relates to the use of a polyamine or a salt, solvate, or derivative thereof, such as spermine or spermidine for the treatment or prevention of a life threatening condition, such as multiple organ failure, in a criti...  
WO/2010/079668
Disclosed is a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. (In the formula, R1, R2, R2', R4, R5, R6, R7, R8 and R8' each represents a hydrogen atom or the like; and R3 represents a hydrogen...  
WO/2010/080581  
WO/2010/081070
The invention relates to novel crystalline forms of (2RS)-1 -(4-ethylphenyl)-2-methyl-3- piperidin-1-yl-propan-1-one. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention i...  
WO/2010/080455
This invention relates to a hydrochloride, malafe, oxalate and tartrate salt forms of 1-(4- { 1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl} -2-ethyl-benzyI)-azetidine- 3-carboxylic acid (Compound I), to pharmaceutical comp...  
WO/2010/081070
The invention relates to novel crystalline forms of (2RS)-1 -(4-ethylphenyl)-2-methyl-3- piperidin-1-yl-propan-1-one. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention i...  
WO/2010/075611
A composition comprising a proanthocyanidin, a proteolytic enzyme and a substance derived from Aloe Vera and/or from a plant of the Agave species, the composition being free of papain. Use of the composition for improving athletic perfor...  
WO/2010/077686
Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorder...  
WO/2010/074284
By searching for a number of various compounds having an activity of inhibiting IL-12/IL-23 production, provided are a medicinal composition and a drug for treating or preventing a disease relating to the hyperproduction of IL-12/IL-23, ...  
WO/2010/075263
Compounds and methods for enhancing erythropoiesis are disclosed. The compound comprises a chemical structure of the formula (I) indicated below, in which R is a glycosyl group. In addition to having an erythropoiesis effect, the compoun...  
WO/2010/073531
Provided is a muscle-building agent comprising a whey protein hydrolyzate having a muscle increasing effect which is highly safe, an aqueous solution of which is highly transparent and which can be used in various products without limita...  
WO/2010/075287
The present invention relates generally to alkyne containing pharmaceutical agents, and in particular, to phenylethynyl-thiophene based metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of...  
WO/2010/075263
Compounds and methods for enhancing erythropoiesis are disclosed. The compound comprises a chemical structure of the formula (I) indicated below, in which R is a glycosyl group. In addition to having an erythropoiesis effect, the compoun...  
WO/2010/075287
The present invention relates generally to alkyne containing pharmaceutical agents, and in particular, to phenylethynyl-thiophene based metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of...  
WO/2010/070094
Description of antigen binding proteins, such as antibodies, which bind to myostatin, polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture...  
WO/2010/069949
The invention provides compounds of Formula (I) for the treatment of multiple sclerosis and other diseases.  
WO/2010/069684
Compounds of formula (I): wherein R1, R2, X1, and X2 are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.  
WO/2010/071794
This invention relates to a novel crystalline form (Form A) of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]- ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid (Compound I), to pharmaceutical compositions comprising this c...  
WO/2010/068264
The invention provides method and composition for alleviating one or more symptoms associated with a medical condition mediated by one or more of a cyclooxygenase, a pro- inflammatory cytokine, and a pro-inflammatory enzyme. The method i...  
WO/2010/068264
The invention provides method and composition for alleviating one or more symptoms associated with a medical condition mediated by one or more of a cyclooxygenase, a pro- inflammatory cytokine, and a pro-inflammatory enzyme. The method i...  
WO/2010/064248
Use of an agent which upregulates an activity or amount of miRNA-9 or miRNA-9* is disclosed for the preparation of a medicament for the treatment of a motor neuron disease (MND).  
WO/2010/064707
Disclosed is a compound which has an excellent S1P1 agonistic activity and is particularly useful as an active ingredient for a prophylactic and/or therapeutic agent for diseases induced by undesirable lymphocyte infiltration or diseases...  
WO/2010/064597
A compound represented by formula (I) or a salt thereof. In formula (I), the symbols are as defined in the description.  
WO/2010/064248
Use of an agent which upregulates an activity or amount of miRNA-9 or miRNA-9* is disclosed for the preparation of a medicament for the treatment of a motor neuron disease (MND).  
WO/2010/057833
Compounds of formula (I): wherein R1, R2, R3, L1, L2, and Y are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.  
WO/2010/058846
Disclosed is a 4,6-diaminonicotinamide compound which is useful as an active ingredient for a pharmaceutical composition, in particular, a pharmaceutical composition for treatment of diseases caused by undesirable and/or abnormal cytokin...  
WO/2010/052563
The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α2-glycoprotein or a functional fragment thereof, methods of decreasing plasma insulin levels, methods of incr...  
WO/2010/052563
The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α2-glycoprotein or a functional fragment thereof, methods of decreasing plasma insulin levels, methods of incr...  

Matches 451 - 500 out of 5,826